Scroll to learn more about our 42 approved medicines and 33 FDA-granted breakthrough therapy designations.
Disclaimer: Some therapies have not been shown.
We have the broadest late-stage retina pipeline, including treatments for neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), diabetic retinopathy (DR), and macular edema following retinal vein occlusion (RVO). Our robust, early-stage pipeline also includes gene therapies and treatments for geographic atrophy (GA).
Ang-2=angiopoietin-2; Ang-Tie=angiopoietin-Tie.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.